The Bayesian Design of Adaptive Clinical Trials

Overview

Journal Int J Environ Res Public Health

Publisher MDPI

Specialties Environmental Health
Public Health

Date 2021 Jan 13

PMID 33435249

Citations 23

Authors

Alessandra Giovagnoli

Affiliations

Soon will be listed here.

Abstract

This paper presents a brief overview of the recent literature on adaptive design of clinical trials from a Bayesian perspective for statistically not so sophisticated readers. Adaptive designs are attracting a keen interest in several disciplines, from a theoretical viewpoint and also-potentially-from a practical one, and Bayesian adaptive designs, in particular, have raised high expectations in clinical trials. The main conceptual tools are highlighted here, with a mention of several trial designs proposed in the literature that use these methods, including some of the registered Bayesian adaptive trials to this date. This review aims at complementing the existing ones on this topic, pointing at further interesting reading material.

Citing Articles

Establishment of a machine learning model for predicting splenic hilar lymph node metastasis.

Ishizu K, Takahashi S, Kouno N, Takasawa K, Takeda K, Matsui K NPJ Digit Med. 2025; 8(1):93.

PMID: 39934302 PMC: 11814149. DOI: 10.1038/s41746-025-01480-x.

A Bayesian adaptive feasibility design for rare diseases.

Churipuy M, Golchi S, Hudson M, Hoa S Contemp Clin Trials Commun. 2024; 42:101392.

PMID: 39618478 PMC: 11605459. DOI: 10.1016/j.conctc.2024.101392.

Adaptive designs in clinical trials: a systematic review-part I.

Ben-Eltriki M, Rafiq A, Paul A, Prabhu D, Afolabi M, Baslhaw R BMC Med Res Methodol. 2024; 24(1):229.

PMID: 39367313 PMC: 11451232. DOI: 10.1186/s12874-024-02272-9.

Couples-based health behavior change interventions: A relationship science perspective on the unique opportunities and challenges to improve dyadic health.

Gouin J, Dymarski M Compr Psychoneuroendocrinol. 2024; 19:100250.

PMID: 39155951 PMC: 11326928. DOI: 10.1016/j.cpnec.2024.100250.

Improving Miscarriage Prevention Research: a survey exploring the expectations of service users and stakeholders (IMPRESS) - a study protocol for a UK-based survey.

Black N, Quenby S, Odendaal J BMJ Open. 2024; 14(7):e085929.

PMID: 39067886 PMC: 11284882. DOI: 10.1136/bmjopen-2024-085929.

References

Thall P, Inoue L, Martin T . Adaptive decision making in a lymphocyte infusion trial. Biometrics. 2002; 58(3):560-8. DOI: 10.1111/j.0006-341x.2002.00560.x. View

Rugo H, Olopade O, DeMichele A, Yau C, J van t Veer L, Buxton M . Adaptive Randomization of Veliparib-Carboplatin Treatment in Breast Cancer. N Engl J Med. 2016; 375(1):23-34. PMC: 5259561. DOI: 10.1056/NEJMoa1513749. View

Zhong W, Koopmeiners J, Carlin B . A two-stage Bayesian design with sample size reestimation and subgroup analysis for phase II binary response trials. Contemp Clin Trials. 2013; 36(2):587-96. PMC: 3757106. DOI: 10.1016/j.cct.2013.03.011. View

Haines L, Perevozskaya I, Rosenberger W . Bayesian optimal designs for Phase I clinical trials. Biometrics. 2003; 59(3):591-600. DOI: 10.1111/1541-0420.00069. View

Johnston K, Bruno A, Pauls Q, Hall C, Barrett K, Barsan W . Intensive vs Standard Treatment of Hyperglycemia and Functional Outcome in Patients With Acute Ischemic Stroke: The SHINE Randomized Clinical Trial. JAMA. 2019; 322(4):326-335. PMC: 6652154. DOI: 10.1001/jama.2019.9346. View

Yin G, Chen N, Lee J . Phase II trial design with Bayesian adaptive randomization and predictive probability. J R Stat Soc Ser C Appl Stat. 2013; 61(2):219-35. PMC: 3832255. DOI: 10.1111/j.1467-9876.2011.01006.x. View

Hey S, Kimmelman J . Are outcome-adaptive allocation trials ethical?. Clin Trials. 2015; 12(2):102-6. PMC: 4482671. DOI: 10.1177/1740774514563583. View

Berry D . Bayesian clinical trials. Nat Rev Drug Discov. 2006; 5(1):27-36. DOI: 10.1038/nrd1927. View

Thall P, Simon R . A Bayesian approach to establishing sample size and monitoring criteria for phase II clinical trials. Control Clin Trials. 1994; 15(6):463-81. DOI: 10.1016/0197-2456(94)90004-3. View

10.

OQuigley J, Conaway M . Continual Reassessment and Related Dose-Finding Designs. Stat Sci. 2011; 25(2):202-216. PMC: 3128794. DOI: 10.1214/10-STS332. View

11.

Ji Y, Liu P, Li Y, Bekele B . A modified toxicity probability interval method for dose-finding trials. Clin Trials. 2010; 7(6):653-63. PMC: 5038924. DOI: 10.1177/1740774510382799. View

12.

Brown A, Gajewski B, Aaronson L, Mudaranthakam D, Hunt S, Berry S . A Bayesian comparative effectiveness trial in action: developing a platform for multisite study adaptive randomization. Trials. 2016; 17(1):428. PMC: 5006258. DOI: 10.1186/s13063-016-1544-5. View

13.

Ashby D . Bayesian statistics in medicine: a 25 year review. Stat Med. 2006; 25(21):3589-631. DOI: 10.1002/sim.2672. View

14.

Cook N, Basu B, Smith D, Gopinathan A, Evans J, Steward W . A phase I trial of the γ-secretase inhibitor MK-0752 in combination with gemcitabine in patients with pancreatic ductal adenocarcinoma. Br J Cancer. 2018; 118(6):793-801. PMC: 5877439. DOI: 10.1038/bjc.2017.495. View

15.

Proschan M, Evans S . Resist the Temptation of Response-Adaptive Randomization. Clin Infect Dis. 2020; 71(11):3002-3004. PMC: 7947972. DOI: 10.1093/cid/ciaa334. View

16.

Lachin J . A review of methods for futility stopping based on conditional power. Stat Med. 2005; 24(18):2747-64. DOI: 10.1002/sim.2151. View

17.

Michos E, Mitchell C, Miller 3rd E, Sternberg A, Juraschek S, Schrack J . Rationale and design of the Study To Understand Fall Reduction and Vitamin D in You (STURDY): A randomized clinical trial of Vitamin D supplement doses for the prevention of falls in older adults. Contemp Clin Trials. 2018; 73:111-122. PMC: 6251709. DOI: 10.1016/j.cct.2018.08.004. View

18.

Schuetze S, Wathen J, Lucas D, Choy E, Samuels B, Staddon A . SARC009: Phase 2 study of dasatinib in patients with previously treated, high-grade, advanced sarcoma. Cancer. 2015; 122(6):868-74. DOI: 10.1002/cncr.29858. View

19.

Barker A, Sigman C, Kelloff G, Hylton N, Berry D, Esserman L . I-SPY 2: an adaptive breast cancer trial design in the setting of neoadjuvant chemotherapy. Clin Pharmacol Ther. 2009; 86(1):97-100. DOI: 10.1038/clpt.2009.68. View

20.

Thall P, Wathen J . Practical Bayesian adaptive randomisation in clinical trials. Eur J Cancer. 2007; 43(5):859-66. PMC: 2030491. DOI: 10.1016/j.ejca.2007.01.006. View